Hikal Ltd Stock Price Today (NSE: HIKAL)
Fundamental Score
Hikal Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Hikal Ltd share price today is ₹221.31, up +1.99% on NSE/BSE as of 31 July 2026. Hikal Ltd (HIKAL) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹2.97K (Cr). The 52-week high for HIKAL share price is ₹330.00 and the 52-week low is ₹146.25. At a P/E ratio of 81.85x, HIKAL is currently trading above its industry average P/E of 34.89x. The company has a Return on Equity (ROE) of 2.95% and a debt-to-equity ratio of 0.57.
Hikal Ltd Share Price Chart — NSE/BSE Historical Performance
Hikal Ltd share price chart: 1.07% return over the past month. 52-week high ₹330.00, 52-week low ₹146.25.
Hikal Ltd — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹217.00 | ₹223.40 | ₹216.40 | ₹221.31 | 1.42L (Cr) | |
| ₹221.46 | ₹222.88 | ₹216.01 | ₹216.99 | 1.23L (Cr) | |
| ₹217.95 | ₹224.00 | ₹216.99 | ₹221.38 | 2.43L (Cr) | |
| ₹221.66 | ₹223.38 | ₹215.35 | ₹216.99 | 1.22L (Cr) | |
| ₹218.11 | ₹224.50 | ₹218.11 | ₹221.98 | 1.97L (Cr) | |
| ₹211.00 | ₹220.00 | ₹208.00 | ₹217.40 | 3.44L (Cr) | |
| ₹213.01 | ₹216.48 | ₹210.15 | ₹211.95 | 1.99L (Cr) | |
| ₹227.26 | ₹228.59 | ₹218.50 | ₹224.74 | 4.62L (Cr) | |
| ₹229.15 | ₹235.90 | ₹225.61 | ₹227.26 | 3.08L (Cr) | |
| ₹234.00 | ₹234.88 | ₹226.22 | ₹228.83 | 2.39L (Cr) |
Hikal Ltd — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹221.88 | ₹252.80 | ₹208.00 | ₹221.31 | -0.26% | |
| ₹193.91 | ₹225.80 | ₹174.97 | ₹221.38 | +14.17% | |
| ₹189.25 | ₹228.00 | ₹189.25 | ₹195.28 | +3.19% | |
| ₹155.00 | ₹194.79 | ₹150.22 | ₹189.25 | +22.10% | |
| ₹187.00 | ₹195.00 | ₹146.25 | ₹147.08 | -21.35% | |
| ₹190.10 | ₹222.80 | ₹177.35 | ₹196.68 | +3.46% | |
| ₹227.79 | ₹229.10 | ₹188.80 | ₹192.58 | -15.46% | |
| ₹224.87 | ₹261.00 | ₹222.28 | ₹226.83 | +0.87% | |
| ₹239.00 | ₹247.00 | ₹218.00 | ₹222.92 | -6.73% | |
| ₹252.00 | ₹257.50 | ₹236.20 | ₹238.35 | -5.42% | |
| ₹255.50 | ₹282.70 | ₹247.05 | ₹251.60 | -1.53% | |
| ₹323.00 | ₹330.00 | ₹244.24 | ₹254.20 | -21.30% |
AI Research Briefing
Powered by Gemini · 2026-04-09
Expensive small-cap recovery play; watch for Q4 results and regulatory risks.
WHAT'S HAPPENING NOW (last 2-4 weeks)
Hikal announced that the promoter Sugandha Hiremath and parties acting in concert have confirmed that there are no encumbrances on their shareholding for FY26. The trading window closed on April 1, 2026, and will re-open 48 hours after the declaration of the company's financial results for the quarter and year ended March 31, 2026.
CORE STORY (THE REAL GAME)
Hikal is a small-cap API and specialty chemical manufacturer. The market narrative is a recovery story based on remediation of regulatory issues and improving capacity utilization after a weak H1 FY26.
- Pharma sector growth
- Q3 FY26 performance
- No promoter pledging
- Successful Q4 recovery
- New order wins in CDMO
- Further regulatory approvals
- Small-cap liquidity risk
- High valuation
- Weak interest coverage
FII decreased holdings by 1.12%, while DII increased holdings by 1.12% [cite: brief].
Indian pharma sector projected to reach $130 billion by 2030.
No - Free Cash Flow 5Y: ₹232.07 Cr [cite: brief].
Monitor Q4 results for confirmation of recovery. Key is regulatory remediation and CDMO pipeline progress.
Primary Thesis Risk
Regulatory issues resurfacing and derailing recovery.
For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Hikal Ltd Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Hikal Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of HIKAL across key market metrics for learning purposes.
Positive Indicators
5 factors identified
Strong Operating Margins (15.17%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Robust Profit Growth (22.51%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Strong Cash Generation (₹314.68 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Balanced Promoter Holding (68.85%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
9 factors identified
Below-Average Return on Equity (2.95%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (3.52%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Premium Valuation Risk (P/E: 81.85x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.
Revenue Contraction (-5.97%)
Observation: Sales decline may indicate market challenges or competitive pressures.
Analysis: Negative revenue growth requires analysis of market conditions.
Limited Growth History (-0.09% CAGR)
Observation: Below-average 5-year sales growth trajectory.
Analysis: Low sales CAGR may indicate mature markets or limited growth opportunities.
Weak Earnings Growth (-22.89% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation.
Stagnant Profit Growth (-22.89% CAGR)
Observation: Limited 5-year profit growth trajectory.
Analysis: Low profit growth may indicate scalability challenges or market maturity.
Weak Interest Coverage (1.11x)
Observation: Limited ability to service debt obligations from earnings.
Analysis: Low interest coverage raises concerns about financial stability.
Limited Institutional Interest (FII+DII: 8.64%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
Hikal Ltd vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Hikal Ltd with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Hikal LtdHikal Ltd...Selected✓ HIKAL • 524735 | 24.6/100 | ₹221.31₹221 | ₹2971.21₹2971.21 | 81.85Average 81.8 Average | 2.95%Poor 2.95% Poor | 3.52%Poor 3.52% Poor | 0.57Good 0.6 Good | -22.89%Poor -22.89% Poor | -0.09%Poor -0.09% Poor | 0.58% |
Sun Pharmaceutical Industries LtdSun Pharmaceuti... SUNPHARMA • 524715 | 66.4/100 | ₹1990.50₹1991 | ₹468821.49₹468821.49 | 37.73Average 37.7 Average | 15.95%Good 15.95% Good | 20.53%Excellent 20.53% Excellent | 0.06Excellent 0.1 Excellent | 16.75%Excellent 16.75% Excellent | 11.78%Good 11.78% Good | 0.82% |
Divis Laboratories LtdDivis Laborator... DIVISLAB • 532488 | 56.3/100 | ₹8056.00₹8056 | ₹193163.97₹193163.97 | 73.64Average 73.6 Average | 16.53%Good 16.53% Good | 21.96%Excellent 21.96% Excellent | 0.00Excellent 0.0 Excellent | 5.71%Good 5.71% Good | 8.67%Good 8.67% Good | 0.41% |
Torrent Pharmaceuticals LtdTorrent Pharmac... TORNTPHARM • 500420 | 51.4/100 | ₹5122.80₹5123 | ₹169902.02₹169902.02 | 77.52Average 77.5 Average | 27.43%Excellent 27.43% Excellent | 15.19%Good 15.19% Good | 1.79Average 1.8 Average | 12.07%Good 12.07% Good | 11.80%Good 11.80% Good | 0.76% |
Cipla LtdCipla Ltd... CIPLA • 500087 | 40.2/100 | ₹1473.20₹1473 | ₹116131.81₹116131.81 | 30.51Average 30.5 Average | 11.60%Average 11.60% Average | 15.49%Good 15.49% Good | 0.02Excellent 0.0 Excellent | 9.94%Good 9.94% Good | 8.01%Good 8.01% Good | 0.90% |
Zydus Lifesciences LtdZydus Lifescien... ZYDUSLIFE • 532321 | 74.1/100 | ₹1078.30₹1078 | ₹115375.77₹115375.77 | 21.26Average 21.3 Average | 21.25%Excellent 21.25% Excellent | 21.14%Excellent 21.14% Excellent | 0.46Excellent 0.5 Excellent | 18.77%Excellent 18.77% Excellent | 12.45%Good 12.45% Good | 0.09% |
Lupin LtdLupin Ltd... LUPIN • 500257 | 83.4/100 | ₹2415.00₹2415 | ₹113976.53₹113976.53 | 20.04Average 20.0 Average | 28.68%Excellent 28.68% Excellent | 29.93%Excellent 29.93% Excellent | 0.29Excellent 0.3 Excellent | 37.02%Excellent 37.02% Excellent | 13.02%Good 13.02% Good | 0.72% |
Mankind Pharma LtdMankind Pharma ... MANKIND • 543904 | 61.5/100 | ₹2469.60₹2470 | ₹105053.91₹105053.91 | 52.29Average 52.3 Average | 13.12%Average 13.12% Average | 13.50%Average 13.50% Average | 0.39Excellent 0.4 Excellent | 10.52%Good 10.52% Good | 18.10%Excellent 18.10% Excellent | 0.04% |
Dr Reddys Laboratories LtdDr Reddys Labor... DRREDDY • 500124 | 41/100 | ₹1148.10₹1148 | ₹102660.46₹102660.46 | 25.62Average 25.6 Average | 11.22%Average 11.22% Average | 13.04%Average 13.04% Average | 0.20Excellent 0.2 Excellent | 15.44%Excellent 15.44% Excellent | 12.09%Good 12.09% Good | 0.65% |
Aurobindo Pharma LtdAurobindo Pharm... AUROPHARMA • 524804 | 24.6/100 | ₹1580.20₹1580 | ₹90035.87₹90035.87 | 25.38Average 25.4 Average | 10.06%Average 10.06% Average | 12.80%Average 12.80% Average | 0.21Excellent 0.2 Excellent | 0.80%Average 0.80% Average | 6.32%Good 6.32% Good | 0.26% |
Laurus Labs LtdLaurus Labs Ltd... LAURUSLABS • 540222 | 34.1/100 | ₹1816.20₹1816 | ₹84016.75₹84016.75 | 93.94Average 93.9 Average | 18.30%Good 18.30% Good | 17.76%Good 17.76% Good | 0.48Excellent 0.5 Excellent | -1.89%Poor -1.89% Poor | 7.19%Good 7.19% Good | 0.13% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Ltd share price468821.49 Cr
- Divis Laboratories Ltd share price193163.97 Cr
- Torrent Pharmaceuticals Ltd share price169902.02 Cr
- Cipla Ltd share price116131.81 Cr
- Zydus Lifesciences Ltd share price115375.77 Cr
Hikal Ltd PE Ratio History
Historical price-to-earnings ratio for HIKAL — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2025 | ₹7.36 | ₹226.83 | 30.8x |
| FY 2024 | ₹5.64 | ₹390.50 | 69.2x |
| FY 2023 | ₹6.36 | ₹303.95 | 47.8x |
| FY 2022 | ₹13.02 | ₹410.10 | 31.5x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Hikal Ltd Dividend History
Annual cash dividends paid by HIKAL — dividend yield 0.58%
| Financial Year | Dividends Paid (₹ Cr) |
|---|---|
| FY 2025 | ₹14.80 Cr |
| FY 2024 | ₹14.80 Cr |
| FY 2023 | ₹12.33 Cr |
| FY 2022 | ₹27.13 Cr |
Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.
Hikal Ltd Quarterly Performance
Latest quarterly metrics for HIKAL — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
-5.97%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
22.51%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
-0.09%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
-22.89%
Compounded annual net profit growth over 5 years
Hikal Ltd Technical Indicators
SMA 50, SMA 200, RSI and volume signals for HIKAL — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Hikal Ltd Financial Statements
Annual income statement, balance sheet and cash flow for Hikal Ltd (HIKAL) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Hikal Ltd
About HIKAL (Hikal Ltd)
Hikal Ltd is a dynamic and innovative pharmaceutical company carving a distinct niche within the global healthcare landscape. Focusing on the intricate synthesis and production of ...specialized chemical compounds, Hikal caters to a diverse spectrum of industries, ranging from pharmaceutical giants developing life-saving medications to pioneering biotechnology firms exploring novel therapies. The company's expertise lies in its ability to meticulously craft chemical intermediates, which serve as the vital building blocks for more complex pharmaceutical formulations and specialty chemicals. Hikal is known for its agility and commitment to delivering high-quality products that meet the stringent requirements of regulated markets, bolstering its reputation as a trusted partner for companies seeking reliable and innovative solutions. Strategically structured into two key operational pillars – Pharmaceuticals and Crop Protection – Hikal optimizes its resources and expertise to address distinct market demands. The Pharmaceutical segment is the core of the company, focusing on research, development, and manufacturing of active pharmaceutical ingredients (APIs) and advanced intermediates. This segment has a wide portfolio of products that are sold to regulated markets across the globe. The Crop Protection segment is a strong growth pillar that manufactures herbicides and pesticides and has seen strong demand. The company is committed to developing sustainable and environmentally friendly products. Hikal leverages its profound understanding of chemical processes and regulatory frameworks to offer a comprehensive suite of services that span the entire product lifecycle. This integrated approach, combined with its state-of-the-art manufacturing facilities and a dedicated team of skilled scientists and engineers, enables Hikal to consistently deliver innovative and customized solutions to its clients. By prioritizing quality, efficiency, and sustainability in all its operations, Hikal is solidifying its position as a valuable partner within the global pharmaceutical and crop protection industries, contributing to the advancement of healthcare and agriculture worldwide.
Company Details
Key Leadership
Corporate Events
HIKAL Share Price: Frequently Asked Questions
What is the current share price of Hikal Ltd?
Hikal Ltd (HIKAL) trades at ₹221.31 on NSE and BSE. Market cap ₹2.97K (Cr). Educational data only.
What is the P/E ratio of Hikal Ltd?
Hikal Ltd has a P/E of 81.85x vs industry average 34.89x.
What is the Bull Run score for Hikal Ltd?
Hikal Ltd has a Bull Run score of 24.6/100 based on 25+ financial parameters.
Does Hikal Ltd pay dividends?
Hikal Ltd has a dividend yield of 0.58%. Past dividends don't guarantee future payments.
What is the ROE of Hikal Ltd?
Hikal Ltd has ROE of 2.95%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Hikal Ltd?
Hikal Ltd has debt-to-equity of 0.57.
Is Hikal Ltd a good investment?
Bull Run gives Hikal Ltd a score of 24.6/100. This is not investment advice — consult a SEBI-registered advisor.